These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 31144617)

  • 1. NRG1 is a critical regulator of differentiation in TP63-driven squamous cell carcinoma.
    Hegde GV; de la Cruz C; Giltnane JM; Crocker L; Venkatanarayan A; Schaefer G; Dunlap D; Hoeck JD; Piskol R; Gnad F; Modrusan Z; de Sauvage FJ; Siebel CW; Jackson EL
    Elife; 2019 May; 8():. PubMed ID: 31144617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interplay and cooperation between SREBF1 and master transcription factors regulate lipid metabolism and tumor-promoting pathways in squamous cancer.
    Li LY; Yang Q; Jiang YY; Yang W; Jiang Y; Li X; Hazawa M; Zhou B; Huang GW; Xu XE; Gery S; Zhang Y; Ding LW; Ho AS; Zumsteg ZS; Wang MR; Fullwood MJ; Freedland SJ; Meltzer SJ; Xu LY; Li EM; Koeffler HP; Lin DC
    Nat Commun; 2021 Jul; 12(1):4362. PubMed ID: 34272396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-activation of super-enhancer-driven CCAT1 by TP63 and SOX2 promotes squamous cancer progression.
    Jiang Y; Jiang YY; Xie JJ; Mayakonda A; Hazawa M; Chen L; Xiao JF; Li CQ; Huang ML; Ding LW; Sun QY; Xu L; Kanojia D; Jeitany M; Deng JW; Liao LD; Soukiasian HJ; Berman BP; Hao JJ; Xu LY; Li EM; Wang MR; Bi XG; Lin DC; Koeffler HP
    Nat Commun; 2018 Sep; 9(1):3619. PubMed ID: 30190462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.
    Alvarado D; Ligon GF; Lillquist JS; Seibel SB; Wallweber G; Neumeister VM; Rimm DL; McMahon G; LaVallee TM
    PLoS One; 2017; 12(7):e0181356. PubMed ID: 28723928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ΔNp63α Suppresses TGFB2 Expression and RHOA Activity to Drive Cell Proliferation in Squamous Cell Carcinomas.
    Abraham CG; Ludwig MP; Andrysik Z; Pandey A; Joshi M; Galbraith MD; Sullivan KD; Espinosa JM
    Cell Rep; 2018 Sep; 24(12):3224-3236. PubMed ID: 30232004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic
    Odintsov I; Lui AJW; Sisso WJ; Gladstone E; Liu Z; Delasos L; Kurth RI; Sisso EM; Vojnic M; Khodos I; Mattar MS; de Stanchina E; Leland SM; Ladanyi M; Somwar R
    Clin Cancer Res; 2021 Jun; 27(11):3154-3166. PubMed ID: 33824166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuregulin-1-mediated ErbB2-ErbB3 signalling protects human trophoblasts against apoptosis to preserve differentiation.
    Fock V; Plessl K; Draxler P; Otti GR; Fiala C; Knöfler M; Pollheimer J
    J Cell Sci; 2015 Dec; 128(23):4306-16. PubMed ID: 26490994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interplay between ΔNp63 and miR-138-5p regulates growth, metastasis and stemness of oral squamous cell carcinoma.
    Zhuang Z; Xie N; Hu J; Yu P; Wang C; Hu X; Han X; Hou J; Huang H; Liu X
    Oncotarget; 2017 Mar; 8(13):21954-21973. PubMed ID: 28423539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TP63-Mediated Enhancer Reprogramming Drives the Squamous Subtype of Pancreatic Ductal Adenocarcinoma.
    Somerville TDD; Xu Y; Miyabayashi K; Tiriac H; Cleary CR; Maia-Silva D; Milazzo JP; Tuveson DA; Vakoc CR
    Cell Rep; 2018 Nov; 25(7):1741-1755.e7. PubMed ID: 30428345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NRG1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors.
    Miyake TM; Pradeep S; Bayraktar E; Stur E; Handley KF; Wu SY; Rodriguez-Aguayo C; Lee JS; Lopez-Berestein G; Coleman RL; Sood AK
    Mol Cancer Ther; 2020 Aug; 19(8):1727-1735. PubMed ID: 32499298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer.
    Ogier C; Colombo PE; Bousquet C; Canterel-Thouennon L; Sicard P; Garambois V; Thomas G; Gaborit N; Jarlier M; Pirot N; Pugnière M; Vie N; Gongora C; Martineau P; Robert B; Pèlegrin A; Chardès T; Larbouret C
    Cancer Lett; 2018 Sep; 432():227-236. PubMed ID: 29935372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An ERBB3/ERBB2 oncogenic unit plays a key role in NRG1 signaling and melanoma cell growth and survival.
    Zhang K; Wong P; Duan J; Jacobs B; Borden EC; Bedogni B
    Pigment Cell Melanoma Res; 2013 May; 26(3):408-14. PubMed ID: 23480537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma.
    Capparelli C; Purwin TJ; Heilman SA; Chervoneva I; McCue PA; Berger AC; Davies MA; Gershenwald JE; Krepler C; Aplin AE
    Cancer Res; 2018 Oct; 78(19):5680-5693. PubMed ID: 30115691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reciprocal inhibition between TP63 and STAT1 regulates anti-tumor immune response through interferon-γ signaling in squamous cancer.
    Jiang Y; Zheng Y; Zhang YW; Kong S; Dong J; Wang F; Ziman B; Gery S; Hao JJ; Zhou D; Zhou J; Ho AS; Sinha UK; Chen J; Zhang S; Yin C; Wei DD; Hazawa M; Pan H; Lu Z; Wei WQ; Wang MR; Koeffler HP; Lin DC; Jiang YY
    Nat Commun; 2024 Mar; 15(1):2484. PubMed ID: 38509096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRP63/TP63 loss accelerates skin tumorigenesis through activation of Wnt/β-catenin signaling.
    Lakshmanachetty S; Balaiya V; Johnson LK; Koster MI
    J Dermatol Sci; 2018 Sep; 91(3):325-328. PubMed ID: 29885760
    [No Abstract]   [Full Text] [Related]  

  • 16. miR-296-5p suppresses EMT of hepatocellular carcinoma via attenuating NRG1/ERBB2/ERBB3 signaling.
    Shi DM; Li LX; Bian XY; Shi XJ; Lu LL; Zhou HX; Pan TJ; Zhou J; Fan J; Wu WZ
    J Exp Clin Cancer Res; 2018 Nov; 37(1):294. PubMed ID: 30486894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The neuregulin-I/ErbB signaling system in development and disease.
    Britsch S
    Adv Anat Embryol Cell Biol; 2007; 190():1-65. PubMed ID: 17432114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuregulin-1 induces cancer stem cell characteristics in breast cancer cell lines.
    Jeong H; Kim J; Lee Y; Seo JH; Hong SR; Kim A
    Oncol Rep; 2014 Sep; 32(3):1218-24. PubMed ID: 25018110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Constitutive activation of neuregulin/ERBB3 signaling pathway in clear cell sarcoma of soft tissue.
    Schaefer KL; Brachwitz K; Braun Y; Diallo R; Wai DH; Zahn S; Schneider DT; Kuhnen C; Vollmann A; Brockhoff G; Gabbert HE; Poremba C
    Neoplasia; 2006 Jul; 8(7):613-22. PubMed ID: 16867224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuregulin 1 expression is a predictive biomarker for response to AV-203, an ERBB3 inhibitory antibody, in human tumor models.
    Meetze K; Vincent S; Tyler S; Mazsa EK; Delpero AR; Bottega S; McIntosh D; Nicoletti R; Winston WM; Weiler S; Feng B; Gyuris J; Weng Z
    Clin Cancer Res; 2015 Mar; 21(5):1106-14. PubMed ID: 25542901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.